Table 5. Crude and adjusted association between anti-HER2 treatment received after diagnosis of brain metastasis (BM) and overall survival (OS) after BM.

Comparison	Crude HR (95% CI)	P a	Adjusted HRb (95% CI)	P a
Bothc vs no anti-HER2	0.24 (0.13–0.44)	<0.001	0.37 (0.19–0.72)	0.003
Bothc vs trastuzumab alone	0.41 (0.21–0.81)	0.011	0.51 (0.25–1.01)	0.055
Bothc vs lapatinib alone	0.65 (0.30–1.42)	0.283	0.60 (0.27–1.31)	0.200
Trastuzumab alone vs no anti-HER2	0.57 (0.39–0.84)	0.005	0.73 (0.49–1.10)	0.13
Lapatinib alone vs no anti-HER2	0.36 (0.21–0.62)	<0.001	0.62 (0.35–1.11)	0.11
Lapatinib alone vs trastuzumab alone	0.63 (0.34–1.16)	0.139	0.85 (0.45–1.58)	0.605

Abbreviations: HR=hazard ratio; CI=confidence interval; BM=brain metastasis.

^aP-value from the proportional hazards model.

^bModel adjusted for age at diagnosis of BM, number of brain metastases lesions, receipt of hormonal treatment after diagnosis of BM, and receipt of chemotherapy after diagnosis of BM.

^cTrastuzumab and lapatinib given sequentially or concomitantly.